|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
ThursdayCopaxone (Glatiramer Acetate Injection) May Protect Against Axonal Injury Over the Long-Term in Relapsing-Remitting Multiple Sclerosis
--CLICK FOR LINK TO COMPLETE ARTICLENew data presented at the European Neurological Society Meeting (ENS) demonstrated key clinical and magnetic resonance imaging (MRI) effects of Copaxone(R) (glatiramer acetate injection) in the treatment of relapsing-remitting multiple sclerosis (RRMS).
Results highlighted sustained beneficial effects on cerebral axonal injury and the value of starting Copaxone treatment early to slow the accumulation of long-term disability as measured by the Expanded Disability Status Scale (EDSS). MRS results suggest beneficial effect of Copaxone on cerebral axonal injury |